Longeveron Inc.
LGVNHealthcare|Biotechnology|US
$1.81
+0.10 (+5.85%)
Tangible Book / Share
$2.61
Cash / Share
$3.21
Clinical Trials (10)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04925024 Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial. | Hypoplastic Left Heart Syndrome | P2 | Active | 40 | RCT, Double-blind | Lomecel-B medicinal signaling cells |
| NCT03525418 Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS) | HLHS | P1P2 | Unknown | 10 | RCT, Double-blind | Longeveron Mesenchymal Stem Cells |
| NCT02065245 AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery | Frailty | P1P2 | Completed | 65 | RCT, Double-blind | Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs), Placebo, Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) |
| NCT03169231 Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty | Aging Frailty | P2 | Completed | 150 | RCT, Double-blind | Longeveron Mesenchymal Stem Cells (LMSCs) |
| NCT05233774 Lomecel-B Effects on Alzheimer's Disease | Mild Alzheimer's Disease | P2 | Completed | 50 | RCT, Double-blind | Allogeneic MSC |
| NCT02587572 Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial | Metabolic Disease, Endothelial Dysfunction | P2 | Withdrawn | — | RCT, Double-blind | Peripheral Intravenous (IV) infusion of LMSCs |
| NCT02982915 Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty | Aging Frailty | P1P2 | Completed | 62 | RCT, Double-blind | Longeveron Mesenchymal Stem Cells (LMSCs), Fluzone High Dose Vaccine |
| NCT04629105 Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER) | ARDS, Human, Covid19 | P1 | Unknown | 70 | RCT, Double-blind | Longeveron Mesenchymal Stem Cells (LMSCs) |
| NCT02600130 Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease | Alzheimer's Disease | P1 | Completed | 33 | RCT, Double-blind | Longeveron Mesenchymal Stem Cells, Placebo |
| NCT02398604 Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome | Hypoplastic Left Heart Syndrome | P1 | Terminated | 5 | RCT, Open-label | Allo-hMSCs, Placebo |